Drug intelligence / Profile preview

MG021

Development stage: Unknown
Lead developer: North China Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal Injection

Overview

MG021 is a recombinant monoclonal antibody developed for the treatment of wet age-related macular degeneration. It targets Human vascular endothelial growth factor (VEGF), a protein that plays a crucial role in the abnormal growth of blood vessels under the retina, which is characteristic of wet AMD. By inhibiting VEGF, MG021 aims to reduce fluid leakage and scarring in the macula, thereby helping to preserve central vision.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on MG021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG021.

Explore the full profile